Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With Apatinib in Relapsed Platinum-resistant Epithelial Ovarian Cancer
NCT04507750Phase 2
Key facts
- Status
- Unknown
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Countries
- 1
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- camrelizumab
- Conditions
- ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Camrelizumab + Apatinib
Camrelizumab 200mg IV Q3W + Apatinib 250mg PO QD
03
Who it enrols
Patients with relapsed platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received at least two lines of systemic chemotherapy.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression Free Survival
Disease Control Rate
Drug Safety
Overall Survival
Beyond the preview
Go deeper on NCT04507750.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507750.